期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PTEN表达水平与转移性结直肠癌患者西妥昔单抗临床获益关系的Meta分析

Meta Analysis on Association of PTEN Expression with Clinical Benefit of Cetuximab Therapy for Metastatic Colorectal Cancer
原文传递
导出
摘要 [目的]评价PTEN表达水平与转移性结直肠癌(mCRC)患者西妥昔单抗临床获益之间的关系,为临床用药和个性化治疗提供参考。[方法]计算机检索PubMed、CNKI、CBM和万方中文数据库,采用Meta分析的方法,评价PETN表达与mCRC患者西妥昔单抗疗效的关系。[结果]共纳入文献14篇,病人总人数1 227人。未经K-ras基因筛选mCRC患者PTEN表达阳性与西妥昔单抗治疗敏感性及无进展生存(PFS)均相关。K-ras野生型mCRC患者PTEN表达阳性与西妥昔单抗治疗PFS、总生存(OS)获益有关。[结论]PTEN表达水平可以作为mCRC患者西妥昔单抗临床获益的预测因素。 [Purpose] To evaluate the association between PTEN expression and the clinical benefit of cetuximab therapy for metastatic colorectal cancer（mCRC） patients. [Methods] Literatures were retrieved in PubMed,CNKI,CBM and Wanfang Data. A Metaanalysis was used to analyze the association between expression of PTEN and cetuximab effects in mCRC patients.[Results] A total of 14 retrospective studies and 1 227 cases were included in the Meta-analysis. The results showed that positive PTEN expression was correlated to sensitivity of cetuximab and progression-free survival（PFS） in mCRC patients unselected of K-ras gene. In patients with wild-type K-ras,positive PTEN predicted longer PFS and overall survival（OS）. [Conclusion] PTEN expression is a predictive factor for clinical benefit in mCRC patients treated with cetuximab.
作者 王琪 胡伟国 宋启斌
机构地区 武汉大学人民医院
出处 《肿瘤学杂志》 CAS 2013年第11期846-853,共8页 Journal of Chinese Oncology
关键词 结直肠肿瘤 PTEN 西妥昔单抗 肿瘤转移 免疫组织化学 META分析 colorectal neoplasms PTEN cetuximab neoplasm metastasis immunohistochemistry Meta analysis
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Karapetis CS,Khambata-Ford S,Jonker DJ,et al. K-ras mutations and benefit from cetuximab in advanced col- orectal cancer [J]. N Engl J Med,2008,359 (17):1757- 1765.
  • 2Van Cutsem E,Kohne CH,Hitre E,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009,360(14) : 1408-1417.
  • 3Ulivi P,Capelli L,Valgiusti M,et al. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer:a single center study [J]. J Transl Med, 2012,10 : 87.
  • 4Park JH,Han SW,Oh DY,et al. Analysis of K-ras, BRAF,PTEN,IGF1R,EGFR intron 1 CA status in bothprimary tumors and paired metastases in determining ben- efit from eetuximab therapy in colon cancer [J]. Cancer Chemother Pharmaeol, 2011,68(4) : 1045-1055.
  • 5Spindler KL, Pallisgaard N, Lindebjerg J, et al. EGFR re- lated mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer[J]. BMC Cancer, 2011,11 : 107.
  • 6Fang-Hua Li,Zhuang-Hua Li,Hui-Yan Luo,Miao-Zhen Qiu,Yu-Hong Li,Rui-Hua Xu,State Key Laboratory of Oncology in Southern China,Department of Medical Oncology,Sun YatSen University Cancer Center,Guangzhou 510060,Guangdong Province,China Fang-Hua Li,Department of Medical Oncology,Shengli Oil Field Central Hospital,Dongying 257034,Shandong Province,China Lin Shen,Department of GI Oncology,Peking University School of Oncology,Beijing Cancer Hospital and Institute,Beijing 100142,China Hui-Zhong Zhang,State Key Laboratory of Oncology in Southern China,Department of Pathology,Sun Yat-Sen University Cancer Center,Guangzhou 510060,Guangdong Province,China.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer[J].World Journal of Gastroenterology,2010,16(46):5881-5888. 被引量：9
  • 7Saridaki Z,Tzardi M,Papadaki C,et al. Impact of K-ras, BRAF,PIK3CA mutations,PTEN,AREG,EREG expres- sion and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients [J]. PLoS One,2011,6(1): e15980.
  • 8Sartore-Bianchi A,Martini M,Molinari F,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies [J]. Cancer Res, 2009,69(5) : 1851-1857.
  • 9Sood A,Mcclain D,Maitra R,et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clini- cal benefit to anti-epidermal growth factor receptor anti- body therapy in patients with K-ras wild-type metastatic colorectal cancer [J]. Clin Colorectal Cancer, 2012,11 (2) : 143-150.
  • 10Frattini M, Saletti P, Romagnani E, et al. PTEN loss of ex- pression predicts cetuximab efficacy in metastatic colorec-tal cancer patients [J]. Br J Cancer,2007,97 (8): 1139- 1145.

二级参考文献24

  • 1Folprecht G,Gruenberger T,Bechstein WO,Raab HR,Lordick F,Hartmann JT,Lang H,Frilling A,Stoehlmacher J,Weitz J,Konopke R,Stroszczynski C,Liersch T,Ockert D,Herrmann T,Goekkurt E,Parisi F,K hne CH.Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial. The Lancet Oncology . 2010
  • 2Van Cutsem E,K hne CH,Hitre E,Zaluski J,Chang Chien CR,Makhson A,D‘Haens G,Pintér T,Lim R,Bodoky G,Roh JK,Folprecht G,Ruff P,Stroh C,Tejpar S,Schlichting M,Nippgen J,Rougier P.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine . 2009
  • 3Sartore-Bianchi A,Martini M,Molinari F,Veronese S,Nichelatti M,Artale S,Di Nicolantonio F,Saletti P,De Dosso S,Mazzucchelli L,Frattini M,Siena S,Bardelli A.PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research . 2009
  • 4Loupakis F,Pollina L,Stasi I,Ruzzo A,Scartozzi M,Santini D,Masi G,Graziano F,Cremolini C,Rulli E,Canestrari E,Funel N,Schiavon G,Petrini I,Magnani M,Tonini G,Campani D,Floriani I,Cascinu S,Falcone A.PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology . 2009
  • 5Heinemann V,Stintzing S,Kirchner T,Boeck S,Jung A.Clinical relevance of EGFRand KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treatment Reviews . 2009
  • 6Lièvre A,Bachet JB,Boige V,Cayre A,Le Corre D,Buc E,Ychou M,Bouché O,Landi B,Louvet C,AndréT,Bibeau F,Diebold MD,Rougier P,Ducreux M,Tomasic G,Emile JF,Penault-Llorca F,Laurent-Puig P.KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology . 2008
  • 7van Zandwijk N,Mathy A,Boerrigter L,Ruijter H,Tielen I,de Jong D,Baas P,Burgers S,Nederlof P.EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors:retroand prospective observations in non-small-cell lung cancer. Annals of Oncology . 2007
  • 8Cunningham D,Humblet Y,Siena S,Khayat D,Bleiberg H,Santoro A,Bets D,Mueser M,Harstrick A,Verslype C,Chau I,Van Cutsem E.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine . 2004
  • 9Aoki Y,Hosaka S,Tachibana N,Karasawa Y,Kawa S,Kiyosawa K.Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas. Pancreas . 2000
  • 10Andreyev, H.J,Norman, A.R,Cunningham, D,Oates, J.R,Clarke, P.A.Kirsten ras mutations in patients with colorectal cancer:the multicenter "RASCAL" study. Journal of the National Cancer Institute . 1998

共引文献8

肿瘤学杂志
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部